P2, N=28, Completed, University Hospitals Bristol and Weston NHS Foundation Trust | Active, not recruiting --> Completed

The introduction of BV has significantly improved real-world survival in ALK+ ALCL. The RSF model enables individualized risk stratification and may support future precision treatment strategies.

In October 2025, becotatug vedotin received its first approval in China for the treatment of adult patients with recurrent/metastatic nasopharyngeal carcinoma who have failed at least two lines of systemic chemotherapy and programmed death-1 (PD-1)/programmed death-1 ligand (PD-L1) inhibitor therapy. This article summarizes the milestones in the development of becotatug vedotin leading to this first approval for nasopharyngeal cancer.

This review provides a comprehensive overview of the toxicity profiles and underlying mechanisms of HER2-targeted ADCs, with a focus on representative agents such as trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd). Furthermore, we discuss emerging approaches to improve ADC safety through structural optimization, including advances in antibody engineering, linker design, and payload selection. This review aims to guide clinicians and researchers in improving the safety and clinical utility of HER2-targeted ADCs in breast cancer treatment.

P1/2, N=255, Recruiting, Salubris Biotherapeutics Inc | N=155 --> 255

P2, N=14, Completed, University of Cologne | Recruiting --> Completed | N=21 --> 14

P2, N=50, Active, not recruiting, PETHEMA Foundation | Completed --> Active, not recruiting

P2, N=41, Recruiting, Jennifer Crombie, MD | Active, not recruiting --> Recruiting

P1, N=121, Active, not recruiting, RemeGen Co., Ltd. | Recruiting --> Active, not recruiting

P2, N=56, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital

P2, N=50, Completed, PETHEMA Foundation | Not yet recruiting --> Completed

Owing to active renal lesions, the patient was treated with prednisolone and cyclophosphamide, which resulted in clinical remission. This case was considered to have T-DM1-associated IgA vasculitis. Although rare, an awareness of the possibility of serious adverse effects associated with drug administration is important.